Management:

Geert C. Mudde, PhD (Founder)
Chief Scientific Officer
Managing Director









Dr. Geert C. Mudde received a Ph.D. in immunology from the University of Utrecht in 1985 and started his international professional career at the Swiss Institute for Asthma and Allergy Research in Davos in 1989. In 1992 he joined the pharmaceutical/biotech industry, where he held several senior management positions such as “Deputy Head of the Immunology Department” at the Novartis Research Institute in Vienna, Austria, “Director of Allergy and Inflammation/Immunology” at the Parke Davis Research Institute in Fresnes, France, “Director Immunology” at Ingenium Pharmaceuticals, Martinsried, Germany, and “VP Exploratory Research” at igeneon AG, Vienna, Austria. Finally, in 2006, while joining Baxter BioScience in Vienna as interim “Director Discovery Research”, Dr. Mudde co-founded the biotech company f-star GmbH, where he served as “Chief Scientific Officer”  until 2009, when he started to prepare for the foundation of S-TARget therapeutics.

C.Langer Christof Langer, MSc, MBA (Founder)
Chief Executive Officer
Managing Director








Christof Langer received an international engineering degree in food- and biotechnology (MSc) from the Vienna University of A pplied Sciences in 1996. In the same year he started his professional career at Baxter BioScience where he held various leading positions in the area of pharmaceutical Management production. 2001 he was promoted to head of production in Vienna; in 2002 he was announced “Director Manufacturing”. In this role he successfully completed a 2 year training to become a Lean-Six-Sigma Black Belt. In 2004, he moved to the Czech Republic to start up and lead Baxter‘s newly built Czech vaccines entity Baxter s.r.o. as “Managing Director”. Starting in 2006, he took responsibility as “Managing Director” in Neuchatel, Switzerland, for Baxter’s blockbuster manufacturing facility Baxter BioScience sarl. After returning to Austria in 2009, he founded an operations & strategy consulting firm whilst preparing for the foundation of S-TARget therapeutics in 2010.